Skip to main
MRNA
MRNA logo

Moderna (MRNA) Stock Forecast & Price Target

Moderna (MRNA) Analyst Ratings

Based on 12 analyst ratings
Hold
Strong Buy 8%
Buy 8%
Hold 58%
Sell 25%
Strong Sell 0%

Bulls say

Moderna is projected to increase product sales from $1.73 billion in 2025 to $2.15 billion in 2026, indicating robust revenue growth prospects. The company has recently completed a $1.5 billion debt deal, strengthening its balance sheet and providing enhanced financial flexibility for future opportunities. Additionally, improvements in manufacturing efficiency are expected to potentially expand gross margins by 10% over the next three years, reflecting a positive shift from the gross margin compression experienced during the pandemic.

Bears say

Moderna's financial outlook is negatively impacted by significant declines in COVID vaccine sales, which are projected to decrease from $18 billion in 2022 to $6.7 billion in 2023, alongside reduced guidance for 2025 due to several emerging headwinds. The company's competitive position in new vaccine markets, particularly for RSV, faces challenges from established products such as Arexvy and Abrysvo, further complicating revenue growth prospects. Compounding these issues is the relatively slow advancement of Moderna's pipeline outside of respiratory vaccines, leading to a substantial reduction in their long-term revenue expectations for COVID-related sales from $3.5 billion to $2.5 billion annually.

Moderna (MRNA) has been analyzed by 12 analysts, with a consensus rating of Hold. 8% of analysts recommend a Strong Buy, 8% recommend Buy, 58% suggest Holding, 25% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Moderna and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Moderna (MRNA) Forecast

Analysts have given Moderna (MRNA) a Hold based on their latest research and market trends.

According to 12 analysts, Moderna (MRNA) has a Hold consensus rating as of Dec 18, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Moderna (MRNA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.